Key Trends Shaping the Future Cellular Immunotherapy Market From 2025-2034: Advancements In Cellular Immunotherapy A Rise Of Off-The-Shelf Allogeneic Therapies

What Is the Estimated Market Size and Growth Rate for the Cellular Immunotherapy Market?
The size of the cellular immunotherapy market has experienced speedy growth in the past. It is projected to increase from $5.72 billion in 2024, surging up to $6.61 billion in 2025, with a compound annual growth rate (CAGR) of 15.7%. This growth during the historic period is believed to have been driven by advancements in cancer treatments, success in the clinical sector, regulatory approvals and an increased prevalence of targeted diseases.

The market size for cellular immunotherapy is anticipated to experience a swift expansion in the coming years. It is projected to increase to a value of $11.27 billion in 2029, with a compound annual growth rate (CAGR) of 14.2%. This surge during the prediction period is due to factors such as the extension to solid tumors, enhancements in manufacturing, healthcare infrastructure, and research funding. Significant trends during this foreseen period encompass investments in research and development, clinical trial data, and combination treatments.

What Are the Forces Behind the Rapid Growth of the Cellular Immunotherapy Market?
The burgeoning research and positive outcomes from clinical trials in cellular immunotherapy are anticipated to propel the expansion of the cellular immunotherapy market throughout the forecast period. There is a concentrated effort among companies to innovate new cellular immunotherapies to combat various illnesses. For example, in June 2022, the Cancer Research Institute, an exclusively dedicated US-based nonprofit organization for the creation of immunotherapy for preventing, treating, and eventually eradicating all forms of cancer, stated in a report that as of April 2022, 2,756 active cell therapy drugs were in the global immuno-oncology pipeline- a 36% surge from the 2,031 agents revealed in 2021's landscape analysis. Although a slight decrease from the previous year's 43% growth, it remains a significant jump. Increased development of cellular immunotherapy in clinical and preclinical stages in 2020, relative to 2019, is expected to broaden the landscape of cellular immunotherapy, thereby contributing to increased revenue for the cellular immunotherapy market's growth.

Get Your Free Sample Now - Explore Exclusive Market Insights:
https://www.thebusinessresearchcompany.com/sample.aspx?id=3435&type=smp

Who Are the Dominant Companies Influencing Cellular Immunotherapy Market Trends?
Major companies operating in the cellular immunotherapy market include Novartis International AG, Gilead Sciences Inc., Apac Biotech, Dendreon Pharmaceuticals LLC, JW CreaGene Co. Ltd, Green Cross Corp, AstraZeneca plc, Bristol Myers Squibb Company, Pfizer Inc., F. Hoffmann-La Roche Ltd., Adicet Bio Inc., ResTORbio Inc., Celyad SA, Merck KGaA, GlaxoSmithKline plc., Johnson & Johnson, Adaptimmune Therapeutics plc, AVROBIO Inc., Cellular Biomedicine Group Inc., Kite Pharma Inc., Juno Therapeutics Inc., Celgene Corporation, Bluebird Bio Inc., Tmunity Therapeutics Inc., Atara Biotherapeutics Inc., Fate Therapeutics Inc., Precision Biosciences Inc., Allogene Therapeutics Inc., CRISPR Therapeutics AG, Sangamo Therapeutics Inc., Intellia Therapeutics Inc., Editas Medicine Inc., Caribou Biosciences Inc., Mammoth Biosciences Inc., Synthego Corporation

How Is the Cellular Immunotherapy Market Evolving?
Firms within the cellular immunotherapy market are intensifying their efforts to create pioneering and enhanced cancer therapies using off-the-shelf allogeneic treatments. Unlike autologous therapy, which uses the patient's own cells, these therapies are derived from donor cells. The benefits of these non-customized treatments include cost-efficiency, the ability to produce on a large scale, quicker production times, and superior quality control. For example, Novartis AG, a Switzerland-based pharmaceutical firm renowned for drug discovery, development, production, and commercialization, received accelerated approval from the U.S Food and Drug Administration (FDA) in May 2022. This approval was awarded for Kymriah (tisagenlecleucel) designed to treat adult patients who have relapsed or refractory (r/r) follicular lymphoma (FL), following at least two instances of systemic therapy. Furthermore, Acepodia, a leading US-based company specializing in next-generation cell immuno-technologies, scheduled a phase 1 clinical trial for August 2020. This trial is aimed at assessing ACE1702, an allogeneic, off-the-shelf NK cell therapy for curing solid tumors.

What Are the Different Segmentations in the Cellular Immunotherapy Market?
The cellular immunotherapy market covered in this report is segmented -

1) By Therapy: Tumor-Infiltrating Lymphocyte (TIL) Therapy, Engineered T Cell Receptor (TCR) Therapy, Chimeric Antigen Receptor (CAR) T Cell Therapy, Natural Killer (NK) Cell Therapy
2) By Primary Indication: B-cell Malignancies, Prostate Cancer, Renal Cell Carcinoma, Liver Cancer, Non-Hodgkin lymphoma, Other Primary Indications
3) By Application: Prostate Cancer, Breast Cancer, Skin Cancer, Ovarian Cancer, Brain Tumor, Lung Cancer, Other Applications

Subsegments:
1) By Tumour-Infiltrating Lymphocyte (TIL) Therapy: Autologous TIL Therapy, Allogeneic TIL Therapy, Other TIL Therapy
2) By Engineered T Cell Receptor (TCR) Therapy: Alpha-Beta TCR Therapy, Gamma-Delta TCR Therapy, Other Engineered TCR Therapy
3) By Chimeric Antigen Receptor (CAR) T Cell Therapy: Autologous CAR T Cell Therapy, Allogeneic CAR T Cell Therapy, CAR T Cell Therapy For Solid Tumors, CAR T Cell Therapy For Hematologic Malignancies, Other CAR T Cell Therapy
4) By Natural Killer (NK) Cell Therapy: Autologous NK Cell Therapy, Allogeneic NK Cell Therapy, NK Cell Therapy With Engineered Modifications, Other NK Cell Therapy

Pre-Book Your Report Now For A Swift Delivery:
https://www.thebusinessresearchcompany.com/report/cellulars-immunotherapy-global-market-report

Which Region Is at the Forefront of the Cellular Immunotherapy Market?
North America was the largest region in the cellular immunotherapy market in 2023. The regions covered in the cellular immunotherapy market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

What Is Covered In The Cellular Immunotherapy Global Market Report?

- Market Size Analysis: Analyze the Cellular Immunotherapy Market size by key regions, countries, product types, and applications.
- Market Segmentation Analysis: Identify various subsegments within the Cellular Immunotherapy Market for effective categorization.
- Key Player Focus: Focus on key players to define their market value, share, and competitive landscape.
- Growth Trends Analysis: Examine individual growth trends and prospects in the Market.
- Market Contribution: Evaluate contributions of different segments to the overall Cellular Immunotherapy Market growth.
- Growth Drivers: Detail key factors influencing market growth, including opportunities and drivers.
- Industry Challenges: Analyze challenges and risks affecting the Cellular Immunotherapy Market.
- Competitive Developments: Analyze competitive developments, such as expansions, agreements, and new product launches in the market.

Unlock Exclusive Market Insights - Purchase Your Research Report Now!
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=3435

Connect with us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ.

Contact Us
Europe: +44 207 1930 708,
Asia: +91 88972 63534,
Americas: +1 315 623 0293 or
Email: mailto:info@tbrc.info

Learn More About The Business Research Company
With over 15,000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Our flagship product, the Global Market Model delivers comprehensive and updated forecasts to support informed decision-making.

This release was published on openPR.